張光裕
➜ 張光裕
職稱
副教授兼腫瘤科主治醫師
電話
(06) 235-3535 ext 5328／5306（實驗室）
傳真
(06) 274-9296
Email
| 個人簡介 |
|---|
|
張光裕醫師現任國立成功大學醫學院藥理學研究所與腫瘤醫學科副教授，同時擔任成大醫院腫瘤醫學部主治醫師。此外，他亦獲聘為國家衛生研究院癌症研究所合聘副研究員。張醫師於高雄醫學大學取得醫學學士（M.D.），隨後於國立成功大學臨床醫學研究所取得博士學位（Ph.D.），並在成大醫院完成住院醫師訓練。2014 年至 2016 年間，張醫師於約翰霍普金斯大學醫學院從事博士後研究。 他的研究領域涵蓋臨床腫瘤學、腫瘤生物學、腫瘤免疫學、訊息傳遞、抗癌藥物開發及早期臨床試驗，並特別專注於頭頸部鱗狀細胞癌與腦瘤之治療抗性及轉移的轉譯研究。張博士對 EGFR–PI3K–AKT 通路及癌症幹性（cancer stemness）有深入探討，近年則致力於腫瘤微環境的研究。 張博士已於《Clinical Cancer Research》、《Redox Biology》、《Journal of Experimental and Clinical Cancer Research》及《Journal of Biomedical Science》等國際期刊發表超過 60 篇經同儕審查的學術論文，並曾獲頒台灣內科學會海報論文獎等殊榮。 |
| 研究領域與成果 |
|---|
|
膠質母細胞瘤（Glioblastoma） 膠質母細胞瘤因受限於血腦屏障（BBB），導致藥物難以穿透，病程進展極快且存活率低。張光裕博士透過分析 GBM 的基因與蛋白質圖譜，揭示分子驅動因子如何形塑複雜的腫瘤生態系統。研究指出，這些免疫與代謝的交互作用不僅惡化病情，同時也為標靶治療創造特定的契機。 |
|
頭頸部癌症（Head and Neck Cancer） 頭頸癌通常表現為具局部侵襲性的疾病，且與接觸致癌物質密切相關。透過整合分子分型研究，張光裕博士的研究闡明了在腫瘤景觀中進行 PI3K／mTOR 雙重抑制的治療潛力。此外，他的研究揭示受組織蛋白酶（cathepsin）調控的介白素-7（IL-7）分泌如何驅動免疫逃逸，為開發更有效且具針對性的療法建立生物學框架。 |
|
泌尿生殖系統癌症（Genitourinary Cancer） 泌尿生殖系統癌症通常與致癌物暴露相關。藉由圖譜化在地泌尿生殖系統腫瘤的基因特徵，張光裕博士為疾病進展提供關鍵數據。這項研究為精準醫學及開發更有效的標靶治療開闢了新的機會。 |
|
臨床試驗（Clinical Trials） 除了基礎生物學研究，張光裕博士亦在早期臨床試驗中評估各種創新療法。他曾評估以 Cetuximab 為基礎的序列療法，結合放射治療與化學治療，以改善局部晚期口腔鱗狀細胞癌患者的預後。此外，張博士的研究也探索腫瘤微環境中的協同策略，包括在實體瘤中結合精胺酸消耗劑 ADI-PEG 20 與 Pembrolizumab，以及針對原發性中樞神經系統淋巴瘤整合 Rituximab、Acalabrutinib 與 Durvalumab 的療法。這些研究旨在銜接代謝或標靶干預與臨床療效之間的差距。 |
|
Publications since 2022 |
|
|---|---|
|
Reasearch article: |
|
| 1. | Chang KY, Hsu YT, Chuang SS, Hsiao CF, Huang TC, Hsieh CY, Yeh SP, Ma WL, Wang MC, Chen TY, Hsueh PR, Wu SJ. Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study. Clinical Cancer Research. 2026 Apr 22. Online ahead of print. doi: 10.1158/1078-0432.CCR-25-3675.（First Author） |
| 2. | Hsueh WT, Chang KY, Tsai CC, Chen KT, Hong ZX, Liu CC, Chu JM, Qiu LY, Lan YY, Chien CH. Revealing the roles of the SH3GLB1/hydrogen peroxide axis in glioblastoma multiforme cells. Oncology Reports. 2026 Jan 19;34(2):15. doi: 10.32604/or.2025.071258.（Co-First Author） |
| 3. | Shen SJ, Chen HC, Lin CL, Thakur A, Onuku R, Chen IC, Li HY, Chang KY, Chuang JY, Yang WB, Lin HY, Shen YR, Liou JP, Chang WC, Hsu TI. Contribution of Prostaglandin E2-Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood-Brain Barrier Crossing Celecoxib Derivative. Advanced Science. 2025 Oct;12(38):e06336. doi: 10.1002/advs.202506336. |
| 4. | Hsueh WT, Chang KY, Chuang JY, Liu MS, Chung PH, Chu JM, Chien CH. SOD2-mediated TMZ-resistant Glioblastoma Cells Exhibit Cross-resistance to Irradiation. Anticancer Research. 2025 Sep;45(9):3711–3718.（Co-First Author） |
| 5. | Taheri Baghmisheh S, Chen CH, Yeh YM, Lin PC, Chen PC, Chan RH, Kang JW, Lee CT, Tsai HJ, Fang YC, Cheung CHA, Chang KY, Chang JY, Chen SH. Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells. Cancer Immunology, Immunotherapy. 2025 Aug;74(9):287. doi: 10.1007/s00262-025-04140-x. |
| 6. | Peng HY, Chang KY, Chang WM, Wu CY, Lee HL, Chang YC, Liu KJ, Shiah SG, Kuo CC, Chang JY. EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. Neoplasia. 2025 Aug;66:101193. doi: 10.1016/j.neo.2025.101193. |
| 7. | Chang YC, Chen SJ, Chen SH, Hsiao SY, Chen LH, Chen CH, Liu CC, Chen YW, Liu KJ, Wu SY, Chu JM, Qiu LY, Chiang WF, Hsieh HP, Hsueh WY, Hsiao JR, Shen MR, Chang JY*, Chang KY*. Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer. Journal of Biomedical Science. 2025 Jul;32(1):69. doi: 10.1186/s12929-025-01154-6.（Corresponding Author） |
| 8. | Chiang NJ, Bai LY, Ho IW, Hsu CH, Liang YH, Chiu CF, Lin CC, Chang KY, Chen SH, Tsai HJ, Lin YP, Chen LT, Lin CC. A phase I study of liposomal Irinotecan（ONIVYDE®）in combination with TAS-102（LONSURF®）in refractory solid tumors. Investigational New Drugs. 2025 Jun;43(3):709–718. doi: 10.1007/s10637-025-01547-2. |
| 9. | Chang YH, Chang KY, Li CH, Chen PL, McGrath JA, Hsu CK. Delayed diagnosis of tuberous sclerosis complex: unveiling low-level TSC2 mosaicism using targeted next-generation sequencing. Clinical and Experimental Dermatology. 2024 Dec;50(1):243–245. doi: 10.1093/ced/llae253. |
| 10. | Wu CY, Chen Y, Lin YJ, Wei KC, Chang KY, Feng LY, Chen KT, Li G, Ren AL, Nitta RT, Wu JY, Cho KB, Pant A, Choi J, Mackall CL, Kim LH, Wu AC, Chuang JY, Huang CY, Jackson CM, Chen PY, Lim M. Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma Progression. Cancer Research. 2024 Dec;84(23):4017–4030. doi: 10.1158/0008-5472.CAN-24-0018. |
| 11. | Yu H, Nishio H, Barbi J, Mitchell-Flack M, Vignali PDA, Zheng Y, Lebid A, Chang KY, Fu J, Higgins M, Huang CT, Zhang X, Li Z, Blosser L, Tam A, Drake C, Pardoll D. Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity. eLife. 2024 Nov;13:RP96812. doi: 10.7554/eLife.96812. |
| 12. | Liu CC, Yang WB, Chien CH, Wu CL, Chuang JY, Chen PY, Chu JM, Cheng SM, Qiu LY, Chang YC, Hwang DY, Huang CY, Lee JS, Chang KY*. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity. Cell Death & Disease. 2024 Jun;15(6):434. doi: 10.1038/s41419-024-06784-6.（Corresponding Author） |
| 13. | Wong CE, Chang Y, Huang CC, Hsu HH, Lai YH, Chang KY, Huang CY, Wang LC, Lee JS, Lee PH. Surgical excision and radiotherapy for brain metastasis from colorectal cancer: How frailty and comorbidity indices influence outcome. Kaohsiung Journal of Medical Sciences. 2024 Apr;40(4):395–403. doi: 10.1002/kjm2.12815. |
| 14. | Yang SJ, Chang ST, Chang KC, Lin BW, Chang KY, Liu YW, Lai MD, Hung LY. Neutralizing IL-16 enhances the efficacy of targeting Aurora-A therapy in colorectal cancer with high lymphocyte infiltration through restoring anti-tumor immunity. Cell Death & Disease. 2024 Jan;15(1):103. doi: 10.1038/s41419-023-06381-z. |
| 15. | Chien CH, Lai CC, Chuang JY, Chu JM, Liu CC, Chang KY*. Role of SH3GLB1 in the Regulation of CD133 expression in GBM Cells. BMC Cancer. 2023 Jul;23(1):713. doi: 10.1186/s12885-023-11211-8.（Corresponding Author） |
| 16. | Ye PH, Li CY, Cheng HY, Anuraga G, Wang CY, Chen FW, Yang SJ, Lee KT, Chang KY*, Lai MD*. A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment. American Journal of Cancer Research. 2023 May;13(5):1952–1969.（Co-Corresponding Author） |
| 17. | Chien CH, Yang WB, Chuang JY, Lee JS, Liao WA, Huang CY, Chen PY, Wu AC, Yang ST, Lai CC, Chi PI, Chu JM, Cheng SM, Liu CC, Hwang DY, Chen SH, Chang KY*. SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma. Journal of Experimental & Clinical Cancer Research. 2022 Jul;41(1):220. doi: 10.1186/s13046-022-02429-8.（Corresponding Author） |
| 18. | Tsai YT, Lo WL, Chen PY, Ko CY, Chuang JY, Kao TJ, Yang WB, Chang KY, Hung CY, Kikkawa U, Chang WC, Hsu TI. Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation. Journal of Biomedical Science. 2022 Mar;29(1):21. doi: 10.1186/s12929-022-00804-3. |
| 19. | Wu AC, Yang WB, Chang KY, Lee JS, Liou JP, Su RY, Cheng SM, Hwang DY, Kikkawa U, Hsu TI, Wang CY, Chang WC, Chen PY, Chuang JY. HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma. Journal of Experimental & Clinical Cancer Research. 2022 Feb;41(1):47. doi: 10.1186/s13046-022-02257-w. |
|
Review article: |
|
| 1. | Chen HC, Chang WC, Chuang JY, Chang KY, Liou JP, Hsu TI. The complex role of eicosanoids in the brain: Implications for brain tumor development and therapeutic opportunities. Biochimica et Biophysica Acta Reviews on Cancer. 2023 Sep;1878(5):188957. doi: 10.1016/j.bbcan.2023.188957. |